Cytogenetic follow-up after bone marrow transplantation for Philadelphia-positive chronic myeloid leukemia

Mario Sessarego, Francesco Frassoni, Raffaella Defferrari, Andrea Bacigalupo, Salvatore Miceli, Cristina Mareni, Franco Ajmar

Research output: Contribution to journalArticlepeer-review


Forty-eight consecutive patients affected by chronic myelogenous leukemia (CML) Philadelphia (Ph) chromosome positive during the chronic phase of the disease underwent allogeneic bone marrow transplantation (BMT). Thirty-five patients had a follow-up over 12 months and were included in a cytogenetic study in order to evaluate the Ph clone eradication. In 25 cases, the Ph chromosome disappeared in all cytogenetic studies, and their hematologic picture is at present apparently normal. Ten patients showed cytogenetic relapse. In one case, the cytogenetic relapse was transitory without any clinical sign of the disease; in three cases, after a transitory cytogenetic relapse, a persistent relapse with clinical picture of progression of the disease occurred; in six cases cytogenetic and a clinical relapse were coincident. Structural chromosomal abnormalities other than Ph were temporarily seen in three cases. The so-called "nonrandom" chromosomal changes typical of the blastic phase were never detected. The reappearing Ph-positive clone spontaneously disappeared in three patients, and their hematologic picture reverted to complete chimerism. The present study confirms that the eradication of the Ph clone is often defective with BMT, and cytogenetic analysis can detect the competition between donor and residual host marrow. Furthermore, the karyotype evolution is different from that found in CML patients treated with conventional chemotherapy.

Original languageEnglish
Pages (from-to)253-261
Number of pages9
JournalCancer Genetics and Cytogenetics
Issue number2
Publication statusPublished - Oct 15 1989

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology


Dive into the research topics of 'Cytogenetic follow-up after bone marrow transplantation for Philadelphia-positive chronic myeloid leukemia'. Together they form a unique fingerprint.

Cite this